Phase 3 N=86 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
Neuromyelitis Optica Spectrum Disorder
Primary: Annual Relapse Rate — 1; 1.30; 0.51; 0.21 Number of relapses
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=4,822 Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. — 894; 1009; 690; 797 Events — p=0.0587
Phase 3 N=95 Labor and Delivery Implant Insertion: A Randomized Controlled Trial
Postpartum Contraception · Family Planning
Primary: Time to Lactogenesis Stage II [Questionnaire] — 65; 67.5 hours
Phase 3 N=260 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Borderline Ovarian Serous Tumor · Micropapillary Serous Carcinoma · Ovarian Serous Adenocarcinoma
Primary: Progression-free Survival (PFS) — 7.2; 13.0 months
Phase 3 N=30 The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma
Rhinitis · Asthma · Allergy
Primary: Change in Symptoms Score After Nasal Allergen Challenge — -5; -4; -1 score on a scale
Phase 3 N=621 Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Volunteers
Surgery
Primary: Responder Rates (%) of Sites Identified for Bacterial Reduction on the Abdomen and Groin — 78; 84; 54; 56 Percent of sites
Phase 3 N=1,436 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
Breast Neoplasms
Primary: Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology…
Phase 3 N=225 Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
Hypersensitivity
Primary: Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled Subjects — 2182; 2 Test site
Phase 3 N=530 A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With a Static Physician's Global Assessment of (sPGA) (0,1) With at Least a 2-point Improvement From Baseline — 6.5; 69.3 Percentage of…
Phase 3 N=41,181 Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
Phase 3 N=230 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data)…
Phase 3 N=418 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
Acute Pain
Primary: Number of Patients Who Respond to Study Medication at the 48-hr Numeric Pain Rating Scale (NRS) Assessment Compared to Placebo. — 38; 49; 52; 12 Participants
Phase 3 N=1,062 Adaptive COVID-19 Treatment Trial (ACTT)
COVID-19
Primary: Time to Recovery — 15; 10 Days — p=<0.001
Phase 3 N=32 Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)
Hypersensitivity
Primary: Cumulative Irritation Total (CIT) Score — 0.0; 20.0; 0.0 Score on a scale
Phase 3 N=79 Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy
Malignant Head and Neck Neoplasm · Mucositis · Radiation-Induced Disorder
Primary: Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS)) — 4.26; 3.68 score on a scale — p=0.004